CD4+ T cell reprogramming

CD4+ T cell reprogramming refers to the biological and therapeutic process of altering the functional phenotype and lineage commitment of CD4+ T helper cells. This phenomenon leverages the inherent plasticity of T cells, which can transition between various states—such as regulatory (Treg), Th1, Th2, and Th17—depending on the cytokine environment and epigenetic landscape (Science Immunology, 2024; Cancer Immunol Res, 2024). In cancer immunotherapy, reprogramming strategies aim to convert immunosuppressive Tregs within the tumor microenvironment into pro-inflammatory effector cells to enhance anti-tumor immunity (PubMed: 39270007). Conversely, in autoimmune and neurodegenerative diseases, the goal is often to reprogram pathogenic effector cells into stable Tregs to restore immune tolerance and promote tissue repair (PNAS, 2024). The molecular mechanisms driving this process involve the dynamic regulation of master transcription factors like Foxp3 and T-bet, as well as epigenetic modifiers such as EZH2 and HDACs, which serve as the primary targets for pharmacological intervention. Understanding CD4+ T cell reprogramming is essential for developing next-generation cellular therapies and small-molecule immunomodulators that go beyond simple immune activation or depletion.

Other names

CD4+ T cell plasticityCD4+ T cell phenotypic switchingT cell lineage conversionInduced regulatory T cell differentiation

Modulation of master transcription factors and epigenetic states to drive phenotypic transitions between CD4+ T cell subsets.